Voyager Therapeutics, Inc. (NASDAQ: VYGR) is a Healthcare company (Biotechnology) with a market capitalization of $95M. The Maz Rating grades it against the other companies in its sector.
Voyager Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.52, Voyager Therapeutics, Inc. trades at 3.8x sales and 0.7x book value. Over the last twelve months it generated about $25M of revenue and a net loss of $107M. It runs an operating margin of -450.1% and a net margin of -416.3%. It shows return on equity of -63.4%, return on invested capital of -67.8% and a free cash flow yield of -116.1%. On the balance sheet: a debt-to-equity ratio of 0.23 and a current ratio of 6.81. Over the past 52 weeks the share price ranged from $1.50 to $5.48, with a beta of 1.20.
Voyager Therapeutics, Inc. does not currently pay a dividend.
21 Wall Street analyst ratings cover the stock: 17 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.